VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
ASRT
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
ASRTAssertio Holdings, Inc.
$23.50$152M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

ASRT logoAssertio Holdings, Inc.(ASRT)Earnings, Financials & Key Ratios

ASRT•NASDAQ
$23.50
Price updated Jun 29, 2026
SectorHealthcareIndustrySpecialty & Generic PharmaSub-IndustrySpecialty pharma brand consolidators
AboutAssertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.Show more
  • Revenue$119M-5.0%
  • EBITDA$13M+844.7%
  • Net Income-$30M-40.7%
  • EPS (Diluted)-4.74-37.4%
  • Gross Margin44.92%-34.5%
  • EBITDA Margin10.77%+894.5%
  • Operating Margin-14.51%+25.9%
  • Net Margin-25.59%-48.2%
  • ROE-28.25%-69.6%

ASRT Price & Volume

Assertio Holdings, Inc. (ASRT) stock price & volume — 10-year historical chart

Loading chart...

Severe Revenue Contraction Threatens Operational Sustainability

Investment Thesis • Updated 2026Q1

VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Liquidity and solvency pressure

Key Thesis Takeaways

  • Assertio Holdings faces a critical inflection point as its core specialty pharmaceutical portfolio experiences rapid erosion, evidenced by a 62.5% revenue decline in 2026Q1.
  • The company's inability to align its fixed SG&A cost structure with this shrinking top line has resulted in deeply negative operating margins of -185.9%, casting doubt on the viability of the current business model.
  • Investors should remain cautious as the firm's cash position remains under pressure, with an accumulated deficit of $722.4 million and ongoing reliance on volatile working capital adjustments to support liquidity.

Verdict Logic

the company's fundamental outlook is severely challenged by a 62.5% quarterly revenue contraction and an operating margin of -185.9%, which suggests that the current cost structure is unsustainable.

ASRT Growth Metrics

Assertio Holdings, Inc. (ASRT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-10.06%
5 Years1.9%
3 Years-8.75%
TTM-14.16%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-16.59%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM-19.06%

Return on Capital

10 Years-16.2%
5 Years-19.83%
3 Years-39.94%
Last Year-11.13%

ASRT Recent Earnings

Assertio Holdings, Inc. (ASRT) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
May 8, 2026
Metric
Actual
Est
EPS
$2.93-53.4%
$1.91
Rev
$10M+10.8%
$9M
Q2 2026
Mar 16, 2026
Metric
Actual
Est
EPS
$1.86+39.0%
$3.05
Rev
$14M+118.5%
$6M
Q4 2025
Nov 10, 2025
Metric
Actual
Est
EPS
$1.65+237.5%
$1.20
Rev
$49M+697.9%
$6M
Q3 2025
Aug 11, 2025
Metric
Actual
Est
EPS
$0.17-70.0%
$0.10
Rev
$29M-0.3%
$29M
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 8, 2026
$2.93vs $1.91-53.4%
$10Mvs $9M+10.8%
Q2 2026Mar 16, 2026
$1.86vs $3.05+39.0%
$14Mvs $6M+118.5%
Q4 2025Nov 10, 2025
$1.65vs $1.20+237.5%
$49Mvs $6M+697.9%
Q3 2025Aug 11, 2025
$0.17vs $0.10-70.0%
$29Mvs $29M-0.3%
Based on last 12 quarters of dataView full earnings history →

Latest ASRT News

Recent stock market news and headlines for Assertio Holdings, Inc. (ASRT)

Business Wire·Jun 16, 2026
Assertio Announces Completion of Merger with Zydus Lifesciences and Fundamental Change and Make-Whole Fundamental Change Relating to its Outstanding 6.50% Convertible Senior Notes due 2027

LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (Nasdaq: ASRT) (“Assertio” or the “Company”) today announced the successful completion of its previously announced merger (the “Merger”) with Zydus Lifesciences Ltd. (“Zydus Lifesciences”) pursuant to the terms of the Agreement and Plan of Merger, dated as of May 13, 2026 (the “Merger Agreement”), between, among others, the Company, Zydus Worldwide DMCC, a limited liability company incorporated under the laws of the United Arab Emirate.

Peers Comparison

Key metrics vs top competitors for Assertio Holdings, Inc. (ASRT)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
ASRT logoASRTAssertio Holdings, Inc.Current
$23.50$151.86M-4.96-5%-25.59%-28.25%—
PAHC logoPAHCPhibro Animal Health Corporation
$34.13$1.38B28.6827.37%6.35%29.49%—
AMRX logoAMRXAmneal Pharmaceuticals, Inc.
$16.92$5.4B76.918.05%4.02%——
SUPN logoSUPNSupernus Pharmaceuticals, Inc.
$47.41$2.73B-69.728.63%-3.74%-2.73%—
PRGO logoPRGOPerrigo Company plc
$11.09$1.53B-1.08-2.75%-43.5%-50.65%—
COLL logoCOLLCollegium Pharmaceutical, Inc.
$37.47$1.22B21.6623.62%9.41%26.74%—

Compare ASRT vs Peers

Assertio Holdings, Inc. (ASRT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs PAHC

Most directly comparable listed peer for ASRT.

Scale Benchmark

vs CVS

Larger-name benchmark to compare ASRT against a more recognizable public peer.

Peer Set

Compare Top 5

vs PAHC, AMRX, SUPN, PRGO

ASRT SEC Filings & Documents

Assertio Holdings, Inc. (ASRT) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 18, 2026·SEC

Material company update

May 13, 2026·SEC

Material company update

May 8, 2026·SEC

10-K Annual Reports

3
FY 2026

Mar 16, 2026·SEC

FY 2025

Mar 12, 2025·SEC

FY 2024

Mar 11, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

May 8, 2026·SEC

FY 2025

Nov 10, 2025·SEC

FY 2025

Aug 11, 2025·SEC

Get notified when ASRT posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

ASRT Frequently Asked Questions

Assertio Holdings, Inc. (ASRT) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Assertio Holdings, Inc.'s revenue?

Assertio Holdings, Inc. (ASRT) reported $102.2M in revenue for fiscal year 2025. This represents a 33952% increase from $0.3M in 1996.

How fast is Assertio Holdings, Inc. growing?

Assertio Holdings, Inc. (ASRT) saw revenue decline by 5.0% over the past year.

Is ASRT profitable?

Assertio Holdings, Inc. (ASRT) reported a net loss of $35.7M for fiscal year 2025.

Dividend & Returns
What is ASRT's return on equity?

Assertio Holdings, Inc. (ASRT) has a return on equity (ROE) of -28.3%. Negative ROE indicates the company is unprofitable.

What is Assertio Holdings, Inc.'s free cash flow?

Assertio Holdings, Inc. (ASRT) had negative free cash flow of $7.1M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in ASRT back in 1996?

Total return calculator · dividends reinvested · 30+ years of data

See returns →